Audiovestibular Function in Infratentorial Superficial Siderosis

Status Completed

Clinical Trial Summary

One in six people in the United Kingdom and over 400 million people worldwide have disabling hearing loss. This figure will double by 2050 as predicted by the World Health Organisation. There is an urgent need to improve our knowledge regarding hearing loss, its underlying mechanisms, optimal diagnostic modalities, reliable and accurate functional and imaging biomarkers. A less-well studied condition associated with progressive hearing loss is infratentorial superficial siderosis (iSS). It results from iron deposition along the surfaces of brain structures which control hearing and balance. It is currently considered uncommon, but may well be under-recognised and therefore under-reported. Despite its severity, our current understanding of its impact on the hearing (auditory) and balance (vestibular) functions is limited, and this has an adverse impact on the treatment offered to these patients. Additionally, iSS patients have been reported to have cognitive impairment yet literature reports of cognitive assessment in iSS are few. The cognitive dysfunction may be specific to iSS or due to progressive hearing impairment or a combination of both, and further studies are required to establish this. Olfaction is also known to be affected in patients with iSS yet is rarely reported in the literature. Due to the significant morbidity and progressive nature, there is a clear need to improve our understanding of the audiovestibular dysfunction resulting from iSS. The aim of this study is to comprehensively assess audiovestibular function in iSS compared to age-related hearing loss and the controls/normative data and as a means to quantify deficits for monitoring disease progression and response to treatment, to assess the impact on the quality of life, to analyse clinically-obtained data (including imaging, cognitive and laboratory data), and correlate these with functional findings in iSS.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04200664
Study type	Observational
Source	University College, London
Contact
Status	Completed
Phase
Start date	February 7, 2020
Completion date	October 19, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05794217` - A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
Completed	`NCT03680365` - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Completed	`NCT03290469` - NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants	N/A
Not yet recruiting	`NCT05955794` - Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes	N/A
Recruiting	`NCT04429750` - Intact Cord Resuscitation in CDH	N/A
Not yet recruiting	`NCT04152876` - Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
Recruiting	`NCT03683966` - MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
Not yet recruiting	`NCT04319796` - European Registry on Rare Neurological Diseases
Completed	`NCT02736565` - Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma	Phase 1
Completed	`NCT05070988` - Oral Health Related Quality of Life of Patients With Rare Diseases: a Qualitative Approach
Completed	`NCT03563677` - Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases	N/A
Recruiting	`NCT05499091` - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN	N/A
Completed	`NCT03954652` - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"	N/A
Recruiting	`NCT05703893` - Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
Enrolling by invitation	`NCT04703179` - Rare and Undiagnosed Disease Research Biorepository
Recruiting	`NCT04024774` - Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases
Recruiting	`NCT06343558` - Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
Not yet recruiting	`NCT06412718` - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Enrolling by invitation	`NCT04654000` - Rheopheresis as Adjuvant Treatment of Calciphylaxis	N/A
Recruiting	`NCT04651439` - Severe Bullous Drug Eruption and Filgrastim	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Audiovestibular Function in Infratentorial Superficial Siderosis — AViSS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms